TPST Stock Performance, Insider Transaction and News

TPST - Tempest Therapeutics, Inc.

Market Cap	11.12M	P/E	-	EPS this Y	20.40%	Ern Qtrly Grth	-
Income	-31.75M	Forward P/E	-0.44	EPS next Y	-3.30%	50D Avg Chg	-26.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-43.00%
Dividend	N/A	Price/Book	0.92	EPS next 5Y	-	52W High Chg	-77.00%
Recommedations	1.50	Quick Ratio	2.14	Shares Outstanding	25.21M	52W Low Chg	7.00%
Insider Own	0.24%	ROA	-54.28%	Shares Float	21.51M	Beta	-2.88
Inst Own	22.43%	ROE	-289.26%	Shares Shorted/Prior	1.92M/2.11M	Price	0.96
Gross Margin	-	Profit Margin	-	Avg. Volume	73,264	Target Price	18.60
Oper. Margin	-	Earnings Date	Nov 6	Volume	31,367	Change	4.35%

Healthcare | Biotechnology | United States

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Tempest Therapeutics, Inc. News

12/06/24	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/05/24	A ‘Reverse Aging’ Guru’s Trail of Failed Businesses
11/27/24	Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock
11/25/24	Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/12/24	Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
11/12/24	Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
10/10/24	Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
10/10/24	Tempest Extends Limited Duration Stockholder Rights Plan
09/20/24	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/18/24	Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
09/05/24	Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/21/24	Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
08/15/24	Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
08/08/24	Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
06/20/24	Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
06/18/24	Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
05/21/24	Tempest to Participate in Upcoming Investor Conferences
05/09/24	Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
04/09/24	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
04/04/24	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST Chatroom

BiotechBreakout Posted - 1 hour ago

$TPST last reported update on TPST website in December 6 regarding the inducement grant. Nothing since. Nothing of orphan status. Silence is golden.

TAKERS1 Posted - 2 hours ago

$TPST Corporate presentation not available anymore on website, no PR on orphan status, no financing news, non compliance at the corner, no more Biz Biz show for Brady….What a mess !!

Winpicks Posted - 7 hours ago

lwhat is status of the second drug? the one Merck can use. - the CEO quoted on tv the Roche agreement is exact copy he used at Merck. he made a template… appreciates efficiency and wouldn’t be surprised AI acceleration $QSI $NVDA eir product i am still here because 2 billion dollar drugs and AI discovery $$$ Ip value competitive advantage for buyer i could be wrong -i cover tech not bio still $tpst should hire me to identify quantify communicate the value of their product with #realroi to create customer value propositions to motivate every stakeholder in the value chain.

ASTS_SPACEMAN Posted - 7 hours ago

$TPST Why do you think they are sitting on news and not putting it out?

Bulltrader988 Posted - 8 hours ago

$TPST from link: date designated december 16th 2024 👀👀 pr next week?? https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1051624

PRG2022 Posted - 10 hours ago

$TPST $0.50 this coming week for sure.

josegodoy Posted - 10 hours ago

$TPST all is -ish - weekly chart - horizontal lines: $0.65 and $0.60 - we could stop here/go lateral (don’t think so) - we could see a descent along the descending trend line (AKA H&S neckline)…. W/ relatively light/normal volume (most likely IMO) and “test” $0.65…$0.60 - strong volume down/thru the neckline towards $0.60 speaks of bearish strength (don’t think so) Strong volume in any direction speak about who’s in-control &/or gaining control - Friday (12/20/24): volume at the end of the day + a stop above the neckline … 🤷 An opinion for entertainment ONLY

PRG2022 Posted - 10 hours ago

$TPST Ugly red candle

Boom1166 Posted - 13 hours ago

$TPST very soon tune out the short stories of fear they are clowns

Harleybug Posted - 16 hours ago

$TPST junk

josegodoy Posted - 19 hours ago

$TPST correct me if I’m wrong here…. one thing that the Spector of a reverse split does, is (a de-facto) suspension of the options market

lousjamsession Posted - 1 day ago

$TPST

lousjamsession Posted - 1 day ago

$TPST...

lousjamsession Posted - 1 day ago

$TPST

Harleybug Posted - 1 day ago

$TPST stock went up 2 Pennie’s just a bunch of retards on this board !

iambaron Posted - 1 day ago

$TPST relax with the price movement here.. I need some time to enter

The1albatross Posted - 1 day ago

$TPST Well if it’s seasonal, this should run soon. Took a chunk

ShowMeThaMonay Posted - 1 day ago

$TPST reversal inbound? Bought some ✊🏻

race2zero Posted - 1 day ago

$TPST closed out this week. I almost exclusively short but I’m jumping to the other side with this. It is going to blow up soon

Jamesstock007 Posted - 1 day ago

$TPST What’s going on? It hit 0.78 on RH!

Wisegill Posted - 1 day ago

$TPST

lousjamsession Posted - 1 day ago

$TPST I feel like I'm watching a lifesaber duel.

PRG2022 Posted - 1 day ago

$TPST Fitty Cent incoming

brotherearl Posted - 1 day ago

$TPST guess you know? i bought MORE!

StockAuthority Posted - 1 day ago

$TPST reversal pattern confirmed today, Morning Star pattern. 43% upside from close to the gap fill as shown also in chart. Large bidder and also potential PR, lots to like at these oversold levels.

Hellozz Posted - 1 day ago

$TPST new to this, Is RS still on table?

sstock22 Posted - 1 day ago

$TPST someone dropped 276,000 shares at close.. wth! lol

GreylockSec Posted - 1 day ago

$TPST Look! it looks like BradyKlaus out there with his $100 million dollar Royalty Funding checks!! ....looks like he's heading south right now over Ontario. Will he make it to the after-hours trading session in time today?!

ThisWi11hurt Posted - 1 day ago

$NUWE still on schedule. It did end up going to almost 30 now which is fine, but could still dump a little more, tbh not that worried about price. Still loading this one DCA with profits. January 1st, Medicare reimbursement ups 4x. Good revenue source for outpatient clinics (dialysis, etc). $TPST $PPBT

Bucky712 Posted - 1 day ago

$TPST

Analyst Ratings

HC Wainwright & Co.	Buy	Aug 15, 24
Piper Sandler	Overweight	Jun 21, 24
HC Wainwright & Co.	Buy	Jun 20, 24
HC Wainwright & Co.	Buy	May 13, 24
HC Wainwright & Co.	Buy	May 10, 24
HC Wainwright & Co.	Buy	Mar 20, 24
Scotiabank	Sector Outperform	Mar 14, 24
Scotiabank	Sector Outperform	Mar 13, 24
HC Wainwright & Co.	Buy	Mar 12, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Woiwode Thomas	Director Director	Apr 29	Buy	2.36	2,118,644	5,000,000	2,118,644	05/03/22
Dubensky Thomas W.	President President	Jan 07	Buy	4.78	2,000	9,560	113,343	01/11/22
Whiting Samuel	Chief Medical Office.. Chief Medical Officer	Jan 06	Buy	4.8048	1,700	8,168	1,901	01/10/22